N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model
摘要:
Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp(3)) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (Delta LLE = 0.3, Delta Fsp(3) = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.
[EN] NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS [FR] NOUVEAUX COMPOSÉS, LEURS COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES D'UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS
申请人:Hoveyda Hamid
公开号:US20110230477A1
公开(公告)日:2011-09-22
The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.
本发明涉及式(I)的新化合物及其在治疗代谢性疾病方面的应用。
Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
申请人:Euroscreen S.A.
公开号:EP2364297A1
公开(公告)日:2011-09-14
[EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR APPLICATION AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:EUROSCREEN SA
公开号:WO2010066682A1
公开(公告)日:2010-06-17
The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.
[EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS POUR UTILISATION DANS LE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX
申请人:EUROSCREEN SA
公开号:WO2011076732A1
公开(公告)日:2011-06-30
The present invention relates to compounds of formula (I) useful in treating and/or preventing gastrointestinal disorders.
[EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS POUR UTILISATION DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
申请人:EUROSCREEN SA
公开号:WO2011076734A1
公开(公告)日:2011-06-30
The present invention relates to compounds of formula (I) (I) useful in treating and/or preventing inflammatory diseases.